Lab Secrets for Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS): Strategies to Leverage NGS-based minimal residual disease (MRD) in Multiple Myeloma (MM) and Acute Lymphoblastic Leukemia (ALL)

De Brouwer, W. (Invited speaker), Van der Straeten, J. (Contributor), Van Riet, I. (Contributor), Bakkus, M. (Contributor)

Activity: Talk or presentationTalk at a public lecture/debate


For decades, pediatric ALLs have been stratified based on the presence of MRD. Likewise, in multiple myeloma, the absence of detectable levels of MRD has demonstrated a clear correlation with longer overall survival. Currently, quantitative allele-specific oligonucleotide (qASO)-PCR is the standard molecular method for MRD detection in these hematologic malignant tumors. However, this technique has some drawbacks that can be overcome by NGS. In this webinar, Dr. Wouter De Brouwer will discuss characteristics, considerations and strategies identified during his laboratory’s NGS MRD validation.
Period24 Feb 2022
Held atAssociation for Molecular Pathology (AMP), United States
Degree of RecognitionInternational